Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.34 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | DGKA | P23743 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1626203 | 0.89 | FAAH (0.48) | PTGER4FAAHAPP | |
| SCHEMBL1623509 | 0.85 | PTGER4 (0.58) | PTGER4FAAHAGTR1AGTR2 | |
| SCHEMBL1624348 | 0.82 | PTGER4 (0.49) | PTGER4TLR7ESR1ESR2AGTR1 | |
| SCHEMBL691805 | 0.82 | PTGER4 (0.66) | PTGER4AGTR1AGTR2LMNA | |
| SCHEMBL1624810 | 0.82 | MEN1 (0.43) | FAAHESR1ESR2AGTR1AGTR2 | |
| SCHEMBL1625185 | 0.82 | MEN1 (0.43) | FAAHTLR7ESR1ESR2AGTR1 | |
| SCHEMBL1626626 | 0.80 | PTGER4 (0.47) | PTGER4TLR7ESR1ESR2AGTR1 | |
| SCHEMBL1625727 | 0.80 | PTGER4 (0.47) | PTGER4TLR7ESR1ESR2LMNA | |
| SCHEMBL1625017 | 0.79 | FAAH (0.40) | FAAHTLR7LMNAMAPK1DGKA | |
| SCHEMBL3955596 | 0.79 | PTGER4 (0.46) | PTGER4TLR7ESR1ESR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928119-B2 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7479564-B2 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | RAQUALIA PHARMA INC. (JP) | 2009-01-20 | — | — | US | disclosed |
| US-20070155732-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | PFIZER INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070066618-A1 | Use of EP4 Receptor Ligands in the Treatment of IL-6 Involved Diseases | PFIZER INC. | 2007-03-22 | — | — | US | disclosed |
| US-7148234-B2 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-7141580-B2 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PFIZER INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1666480-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as intermediates for Anti-Inflammatory And Analgesic Agents. | PFIZER PHARMACEUTICALS INC. (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-1326864-B1 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMA (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-6710054-B2 | CONTAINING SULFONYLAMINOCARBONYL GROUPS; PROSTAGLANDIN INHIBITORS | PFIZER INC | 2004-03-23 | — | — | US | disclosed |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | SHIMOJO MASATO | 2003-12-25 | — | — | US | disclosed |
| EP-1326864-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| EP-1326606-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PFIZER PHARMACEUTICALS INC. (JP) | 2002-06-20 | — | — | US | disclosed |
| WO-2002032422-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002032900-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | PTGER4 51/4885FAAH 146/4885TLR7 1864/4885 |
| US-20070066618-A1 | Use of EP4 Receptor Ligands in the Treatment of IL-6 Involved Diseases | PTGER4, PTGER1, IL6 | PTGER4 1/4885FAAH 585/4885TLR7 444/4885 |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PTGER4, PTGER1, IL6 | PTGER4 1/4885FAAH 585/4885TLR7 444/4885 |
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | PTGER4 55/4885FAAH 140/4885TLR7 1819/4885 |
| US-20070155732-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | PTGS1, PTGS2, PTGES | PTGER4 6/4885FAAH 270/4885TLR7 2212/4885 |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885FAAH 102/4885TLR7 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.